TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Follow-up colonoscopy rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients progressing in curve severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Electromyography (EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional independence scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of persons agreeing to participate among those referred
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of contacts made with community health worker
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of detection of SARS-CoV-2 N antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in saliva secretory IgA (SIgA) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in upper respiratory tract infections rate
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative delirium-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in LDL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Adverse Events of Special Interests
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of index ulcers closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MRD Negative Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival and Success rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants with Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate and respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atelectasis in chest x ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial blood gases test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to diagnosis of SBO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative assessment of acceptability - ABC course facilitators
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rates - Self-report outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eradication rate of helicobacter pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients Screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients Recruited Into the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Eligible Patients That Were Not Enrolled or Refused to Participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention of Study Participants (Drop Out)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention of Study Participants (Lost to Follow-up)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Control of CNS disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of clinically related non-major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of mortality (cardiovascular and all-cause)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPAP adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CPAP efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSA related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of repeat interventions prior to resolution of abscess(s)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in RU SATED Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Good hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving the uterus contracted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstetrician does not feel fatigued
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of Antibody-Mediated Rejection (ABMR)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of mixed Antibody-Mediated Rejection / T-Cell Mediated Rejection (ABMR/TCMR)
Endpoint domain: Adverse events/effects
Primary endpoint: Kidney transplant function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease in CESD-R scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in GAD-7 scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in WEMWBS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: thoracoabdominal (cirtometry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diaphragmatic motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of Dysgeusia
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Severe Dysgeusia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Onset of Severe Dysgeusia
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution/Improvement of Dysgeusia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to discharge after intranasal medication administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of serum 5-MTHF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC (0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spatio-temporal Gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LL-37 levels in crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve up to the Last Specified Sampling Time (AUC0-t) of Darigabat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Darigabat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reasons for life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cultural connectedness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Incidence of LIFU-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reward network activity in response to alcohol cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Upper Extremity Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limit of Stability (LOS)-Movement Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limit of Stability (LOS)-Endpoint Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety measured by visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of Anti-CMV Neutralizing Antibodies (nAbs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold-Rise (GMFR) of Anti-CMV nAbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rPFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in fecal state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6-month Progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: 3-dimensional wall enhancement volume rate (3D-WEVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post EST bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in child and parental attitudes towards therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in view of emotions as changeable
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in view of personality as changeable
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Critical Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Time in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Management Indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of survivors
Endpoint domain: Mortality/survival
Primary endpoint: Respiration Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of volunteers recruited, trained, and retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total per cycle dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Grade A embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Occurrence of intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of Grade ≥2 Corneal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left atrial volume indexed (LAVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numerical Rating Scale (NRS) Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of team-focused implementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appropriateness of team-focused implementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of team-focused implementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of time to complete study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of study data collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of assessing physiological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of intervention to participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of intervention and risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum level of Ca15-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum level of interferon gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PTSD Status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities (WOMAC) Osteoarthritis (OA) Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety after UTAA09 injection treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy after UTAA09 injection treatment
Endpoint domain: Physiological/clinical
Primary endpoint: Sensitivity and specificity of cfDNA methylation model
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SL-172154
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor activity of SL-172154
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with PLT >75×10^9/L or doubling from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Compassionate Love Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically significant abnormal changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant abnormal changes in laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type and severity of ocular and systemic AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Remineralization of initial carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Alcohol-related Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change in patient reported outcomes (PRO)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delta Small Bowel Water (DeltaSBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of serum LDH levels from baseline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in total hemoglobin levels (g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in total number of units of packed red blood cells (pRBCs) transfused through Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants with HPV-related OPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of successful epidural blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daily Sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trauma-Related Cognitions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Self-Reported Arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Stress Management Skill Use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects maintained at HBV DNA <29 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective Information Processing
Endpoint domain: Cognitive functioning
Primary endpoint: Number of Participants Practicing Safe Lead Exposure Prevention Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glasgow Outcomes Scale-Extended (GOSE) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pre-exposure prophylaxis (PrEP) uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pre-exposure prophylaxis (PrEP) persistence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pre-exposure prophylaxis (PrEP) adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pulse waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to acquire cardiac ultrasound images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero to the last time of quantifiable concentration (AUC(0-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC(INF))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral vasculature imaging enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in annualized number of severe VOCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with successful neutrophil engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transplant-related mortality within 100 days after beam-101 treatment
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline Clinical foot type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Calcaneal position in frontal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Medial longitudinal arch (MLA) height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infection Rehospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Number of responders according to OMERACT-OARSI responder criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle activity in the form of normalized root mean square
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety state before endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity before endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-endoscopy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep variability
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of cutaneous response to Nickel challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Loss of lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of ClearPlasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure monitor accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of saliva collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TB (all forms - PTB / EPTB)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of GPLD1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SPPB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of serum oligosaccharides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum level of total immunoglobulin (Ig)G level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentration of pro-somatostatin 1-64
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf or AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of occurrences and severity of pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of Extracorporeal Membrane Oxygenation (ECMO) support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Brain blood flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Attacks Occurring per Three-Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from Treatment (On-demand Therapy) to Symptom Improvement/Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Hospitalizations per Year Associated With Management of HAE nC1-INH or NHAE nC1-INH
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum tolerated dose (MTD) of radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes